Latest Casdin Capital, LLC Stock Portfolio
$1.31Billion– No. of Holdings #38
Casdin Capital, LLC Performance:
2024 Q2: 1.19%YTD: 11.09%2023: -13.17%
Performance for 2024 Q2 is 1.19%, and YTD is 11.09%, and 2023 is -13.17%.
About Casdin Capital, LLC and 13F Hedge Fund Stock Holdings
Casdin Capital, LLC is a hedge fund based in NEW YORK, NY. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $2.7 Billions. In it's latest 13F Holdings report, Casdin Capital, LLC reported an equity portfolio of $1.3 Billions as of 30 Jun, 2024.
The top stock holdings of Casdin Capital, LLC are BLFS, RVMD, SRPT. The fund has invested 14.2% of it's portfolio in BIOLIFE SOLUTIONS INC and 13.1% of portfolio in REVOLUTION MEDICINES INC.
The fund managers got completely rid off ABCELLERA BIOLOGICS INC (ABCL) and SINGULAR GENOMICS SYSTEMS IN (OMIC) stocks. They significantly reduced their stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), MONTE ROSA THERAPEUTICS INC (GLUE) and STRUCTURE THERAPEUTICS INC. Casdin Capital, LLC opened new stock positions in CONTINEUM THERAPEUTICS INC, GUARDANT HEALTH INC (GH) and SINGULAR GENOMICS SYSTEMS IN (OMIC). The fund showed a lot of confidence in some stocks as they added substantially to KYVERNA THERAPEUTICS INC, ILLUMINA INC (ILMN) and CENTURY THERAPEUTICS INC (IPSC).
The top stock holdings of Casdin Capital, LLC are BLFS, RVMD, SRPT. The fund has invested 14.2% of it's portfolio in BIOLIFE SOLUTIONS INC and 13.1% of portfolio in REVOLUTION MEDICINES INC.
The fund managers got completely rid off ABCELLERA BIOLOGICS INC (ABCL) and SINGULAR GENOMICS SYSTEMS IN (OMIC) stocks. They significantly reduced their stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), MONTE ROSA THERAPEUTICS INC (GLUE) and STRUCTURE THERAPEUTICS INC. Casdin Capital, LLC opened new stock positions in CONTINEUM THERAPEUTICS INC, GUARDANT HEALTH INC (GH) and SINGULAR GENOMICS SYSTEMS IN (OMIC). The fund showed a lot of confidence in some stocks as they added substantially to KYVERNA THERAPEUTICS INC, ILLUMINA INC (ILMN) and CENTURY THERAPEUTICS INC (IPSC).
Casdin Capital, LLC Equity Portfolio Value
Last Reported on: 18 Oct, 2024
Casdin Capital, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Casdin Capital, LLC made a return of 1.19% in the last quarter. In trailing 12 months, it's portfolio return was -2.09%.
New Buys
| Ticker | $ Bought |
|---|---|
| contineum therapeutics inc | 5,224,290 |
| guardant health inc | 2,888,000 |
| grail inc | 1,229,580 |
| singular genomics systems in | 372,890 |
New stocks bought by Casdin Capital, LLC
Additions
| Ticker | % Inc. |
|---|---|
| kyverna therapeutics inc | 283 |
| illumina inc | 93.55 |
| century therapeutics inc | 61.88 |
| relay therapeutics inc | 13.81 |
| genedx holdings corp | 12.43 |
| intellia therapeutics inc | 6.67 |
| standard biotools inc | 3.31 |
| sarepta therapeutics inc | 0.42 |
Additions to existing portfolio by Casdin Capital, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| alnylam pharmaceuticals inc | -52.51 |
| monte rosa therapeutics inc | -48.91 |
| structure therapeutics inc | -37.32 |
| revolution medicines inc | -21.55 |
Casdin Capital, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| abcellera biologics inc | -10,691,400 |
| singular genomics systems in | -680,742 |
Casdin Capital, LLC got rid off the above stocks
Sector Distribution
Casdin Capital, LLC has about 88.4% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 88.4 |
| 7 | |
| Others | 4.6 |
Market Cap. Distribution
Casdin Capital, LLC has about 22% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 40.2 |
| MID-CAP | 29.4 |
| LARGE-CAP | 22 |
| UNALLOCATED | 4.6 |
| MICRO-CAP | 3.8 |
Stocks belong to which Index?
About 61.2% of the stocks held by Casdin Capital, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 57.4 |
| Others | 38.8 |
| S&P 500 | 3.8 |
Casdin Capital, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Casdin Capital, LLC
Casdin Capital, LLC has 38 stocks in it's portfolio. About 77% of the portfolio is in top 10 stocks. LAB proved to be the most loss making stock for the portfolio. SMFR was the most profitable stock for Casdin Capital, LLC last quarter.
Last Reported on: 18 Oct, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABCL | abcellera biologics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ABSI | absci corporation | 0.23 | 973,260 | 2,997,640 | unchanged | 0.00 | ||
| ALNY | alnylam pharmaceuticals inc | 3.15 | 170,000 | 41,310,000 | reduced | -52.51 | ||
| BEAM | beam therapeutics inc | 1.21 | 675,000 | 15,815,200 | unchanged | 0.00 | ||
| BLFS | biolife solutions inc | 14.25 | 8,707,160 | 186,595,000 | unchanged | 0.00 | ||
| BPMC | blueprint medicines corp | 2.69 | 326,378 | 35,177,000 | unchanged | 0.00 | ||
| CDXS | codexis inc | 0.47 | 2,000,000 | 6,200,000 | unchanged | 0.00 | ||
| DNA | ginkgo bioworks holdings inc | 0.04 | 36,493 | 487,993 | unchanged | 0.00 | ||
| DNLI | denali therapeutics inc | 2.31 | 1,300,000 | 30,186,000 | unchanged | 0.00 | ||
| EXAS | exact sciences corp | 2.10 | 650,000 | 27,462,500 | unchanged | 0.00 | ||
| FDMT | 4d molecular therapeutics in | 1.28 | 800,000 | 16,792,000 | unchanged | 0.00 | ||
| GH | guardant health inc | 0.22 | 100,000 | 2,888,000 | new | |||
| GLUE | monte rosa therapeutics inc | 0.07 | 261,014 | 976,192 | reduced | -48.91 | ||
| ILMN | illumina inc | 3.83 | 480,000 | 50,102,400 | added | 93.55 | ||
| IPSC | century therapeutics inc | 1.01 | 5,190,510 | 13,235,800 | added | 61.88 | ||
| KRON | kronos bio inc | 0.01 | 123,839 | 153,560 | unchanged | 0.00 | ||
| LAB | standard biotools inc | 8.64 | 63,959,700 | 113,209,000 | added | 3.31 | ||
| NTLA | intellia therapeutics inc | 3.42 | 2,000,000 | 44,760,000 | added | 6.67 | ||
| OMIC | singular genomics systems in | 0.03 | 44,129 | 372,890 | new | |||
| OMIC | singular genomics systems in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||